Emergence client Ethicann Pharmaceuticals, a company that sources pharmaceutical-grade botanically sourced cannaboid oils to formulate ethical drugs has closed a successful initial financing round. Several Canadian and US venture funds and high net worth individuals and entrepreneurs with considerable industry experience are the investors.
One of Ethicann’s recent milestones saw their US subsidiary holding successful Pre-IND meeting with the US Food and Drug Administration to discuss the 505(b)2 requirements for a marketing approval for its first product (CAN-001) to treat chemotherapy-induced nausea and vomiting.
For more details on the company and their latest achievement, click here.
.